404 related articles for article (PubMed ID: 18266272)
1. Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei.
Reyes-Sandoval A; Sridhar S; Berthoud T; Moore AC; Harty JT; Gilbert SC; Gao G; Ertl HC; Wilson JC; Hill AV
Eur J Immunol; 2008 Mar; 38(3):732-41. PubMed ID: 18266272
[TBL] [Abstract][Full Text] [Related]
2. Single-dose protection against Plasmodium berghei by a simian adenovirus vector using a human cytomegalovirus promoter containing intron A.
Sridhar S; Reyes-Sandoval A; Draper SJ; Moore AC; Gilbert SC; Gao GP; Wilson JM; Hill AV
J Virol; 2008 Apr; 82(8):3822-33. PubMed ID: 18256155
[TBL] [Abstract][Full Text] [Related]
3. A strong CD8+ T cell response is elicited using the synthetic polypeptide from the C-terminus of the circumsporozoite protein of Plasmodium berghei together with the adjuvant QS-21: quantitative and phenotypic comparison with the vaccine model of irradiated sporozoites.
Meraldi V; Romero JF; Kensil C; Corradin G
Vaccine; 2005 Apr; 23(21):2801-12. PubMed ID: 15780728
[TBL] [Abstract][Full Text] [Related]
4. Immunization with a circumsporozoite epitope fused to Bordetella pertussis adenylate cyclase in conjunction with cytotoxic T-lymphocyte-associated antigen 4 blockade confers protection against Plasmodium berghei liver-stage malaria.
Tartz S; Kamanova J; Simsova M; Sebo P; Bolte S; Heussler V; Fleischer B; Jacobs T
Infect Immun; 2006 Apr; 74(4):2277-85. PubMed ID: 16552058
[TBL] [Abstract][Full Text] [Related]
5. Progress in DNA-based heterologous prime-boost immunization strategies for malaria.
Moore AC; Hill AV
Immunol Rev; 2004 Jun; 199():126-43. PubMed ID: 15233731
[TBL] [Abstract][Full Text] [Related]
6. MHC class I-dependent presentation of exoerythrocytic antigens to CD8+ T lymphocytes is required for protective immunity against Plasmodium berghei.
White KL; Snyder HL; Krzych U
J Immunol; 1996 May; 156(9):3374-81. PubMed ID: 8617963
[TBL] [Abstract][Full Text] [Related]
7. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses.
Prieur E; Gilbert SC; Schneider J; Moore AC; Sheu EG; Goonetilleke N; Robson KJ; Hill AV
Proc Natl Acad Sci U S A; 2004 Jan; 101(1):290-5. PubMed ID: 14694197
[TBL] [Abstract][Full Text] [Related]
8. IL-12 and NK cells are required for antigen-specific adaptive immunity against malaria initiated by CD8+ T cells in the Plasmodium yoelii model.
Doolan DL; Hoffman SL
J Immunol; 1999 Jul; 163(2):884-92. PubMed ID: 10395683
[TBL] [Abstract][Full Text] [Related]
9. IL-12p40-independent induction of protective immunity upon multiple Plasmodium berghei irradiated sporozoite immunizations.
Romero JF; Ibrahim GH; Renggli J; Himmelrich H; Graber P; Corradin G
Parasite Immunol; 2007 Nov; 29(11):541-8. PubMed ID: 17944743
[TBL] [Abstract][Full Text] [Related]
10. Protection against malaria by Plasmodium yoelii sporozoite surface protein 2 linear peptide induction of CD4+ T cell- and IFN-gamma-dependent elimination of infected hepatocytes.
Wang R; Charoenvit Y; Corradin G; De La Vega P; Franke ED; Hoffman SL
J Immunol; 1996 Nov; 157(9):4061-7. PubMed ID: 8892640
[TBL] [Abstract][Full Text] [Related]
11. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
12. Complete protection against P. berghei malaria upon heterologous prime/boost immunization against circumsporozoite protein employing Salmonella type III secretion system and Bordetella adenylate cyclase toxoid.
Tartz S; Rüssmann H; Kamanova J; Sebo P; Sturm A; Heussler V; Fleischer B; Jacobs T
Vaccine; 2008 Nov; 26(47):5935-43. PubMed ID: 18804138
[TBL] [Abstract][Full Text] [Related]
13. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes.
Trimnell A; Takagi A; Gupta M; Richie TL; Kappe SH; Wang R
J Immunol; 2009 Nov; 183(9):5870-8. PubMed ID: 19812194
[TBL] [Abstract][Full Text] [Related]
14. CD8+ T effector memory cells protect against liver-stage malaria.
Reyes-Sandoval A; Wyllie DH; Bauza K; Milicic A; Forbes EK; Rollier CS; Hill AV
J Immunol; 2011 Aug; 187(3):1347-57. PubMed ID: 21715686
[TBL] [Abstract][Full Text] [Related]
15. Immunological responses of neonates and infants to DNA vaccines.
Sedegah M; Hoffman SL
Methods Mol Med; 2006; 127():239-51. PubMed ID: 16988458
[TBL] [Abstract][Full Text] [Related]
16. Protective antibody and CD8+ T-cell responses to the Plasmodium falciparum circumsporozoite protein induced by a nanoparticle vaccine.
Kaba SA; McCoy ME; Doll TA; Brando C; Guo Q; Dasgupta D; Yang Y; Mittelholzer C; Spaccapelo R; Crisanti A; Burkhard P; Lanar DE
PLoS One; 2012; 7(10):e48304. PubMed ID: 23144750
[TBL] [Abstract][Full Text] [Related]
17. Plasmodium berghei sporozoite challenge of vaccinated BALB/c mice leads to the induction of humoral immunity and improved function of CD8(+) memory T cells.
Tartz S; Deschermeier C; Retzlaff S; Heussler V; Sebo P; Fleischer B; Jacobs T
Eur J Immunol; 2013 Mar; 43(3):693-704. PubMed ID: 23229763
[TBL] [Abstract][Full Text] [Related]
18. Can malaria DNA vaccines on their own be as immunogenic and protective as prime-boost approaches to immunization?
Hoffman SL; Doolan DL
Dev Biol (Basel); 2000; 104():121-32. PubMed ID: 11713810
[TBL] [Abstract][Full Text] [Related]
19. Nematode-induced interference with the anti-Plasmodium CD8+ T-cell response can be overcome by optimizing antigen administration.
Kolbaum J; Tartz S; Hartmann W; Helm S; Nagel A; Heussler V; Sebo P; Fleischer B; Jacobs T; Breloer M
Eur J Immunol; 2012 Apr; 42(4):890-900. PubMed ID: 22161305
[TBL] [Abstract][Full Text] [Related]
20. Immunogenicity of novel nanoparticle-coated MSP-1 C-terminus malaria DNA vaccine using different routes of administration.
Cherif MS; Shuaibu MN; Kurosaki T; Helegbe GK; Kikuchi M; Yanagi T; Tsuboi T; Sasaki H; Hirayama K
Vaccine; 2011 Nov; 29(48):9038-50. PubMed ID: 21939717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
